enGene Therapeutics (ENGN) Other Non Operating Income (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Other Non Operating Income of -$177000.0 for Q2 2026, up 13.66% year-over-year from -$155729.6 in Q2 2025, and up 63.73% quarter-over-quarter from -$488000.0 in Q1 2026.
enGene Therapeutics (ENGN) Other Non Operating Income (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Other Non Operating Income for 4 consecutive years, with -$177000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income rose 13.66% year-over-year to -$177000.0; the TTM figure through Apr 2026 stood at -$1.1 million (down 246.1% YoY), while the FY2025 annual figure was -$569000.0, down 403.54% from the prior year.
- Other Non Operating Income improved to -$177000.0 in Q2 2026 per ENGN's latest filing, from -$488000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $396000.0 in Q4 2023 and bottomed at -$488000.0 in Q1 2026.
- Historically, Other Non Operating Income has averaged -$152076.9 across 4 years, with a median of -$177000.0 in 2026.
- Annual changes were most pronounced in 2025 — Other Non Operating Income soared 110.11% — and 2026, when it tumbled 1418.92%.
- enGene Therapeutics' Other Non Operating Income stood at $396000.0 in 2023, then sank by 123.48% to -$93000.0 in 2024, then plunged by 30.11% to -$121000.0 in 2025, then tumbled by 46.28% to -$177000.0 in 2026.
- Business Quant data shows ENGN's Other Non Operating Income at -$177000.0 in Q2 2026, -$488000.0 in Q1 2026, and -$121000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -177,000.00 |
| Jan 31, 2026 | -488,000.00 |
| Oct 31, 2025 | -121,000.00 |
| Jul 31, 2025 | -280,000.00 |
| Apr 30, 2025 | -205,000.00 |
| Jan 31, 2025 | 37,000.00 |
| Oct 31, 2024 | -93,000.00 |
| Jul 31, 2024 | -47,000.00 |
| Apr 30, 2024 | 91,000.00 |
| Jan 31, 2024 | -366,000.00 |
| Oct 31, 2023 | 396,000.00 |
| Jul 31, 2023 | -439,000.00 |
| Jan 31, 2023 | -285,000.00 |